文献速递肿瘤 PET/CT

随访18F-FDG PET对肺癌患者管理的影响:一项Meta分析

Impact of Follow-up 18F-FDG PET on the Management in Patients With Lung Cancer: A Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该Meta分析纳入8项研究共523例肺癌患者,评估随访18F-FDG PET检测复发/转移对管理决策的影响。管理改变率范围为28.6%至79.2%,合并效应量为61.4%(95%CI 49.5%-72.7%;I²=85.7%)。作者认为18F-FDG PET对复发肺癌患者的管理有重大影响,建议在常规影像可疑或提示复发/转移、肿瘤标志物升高或出现临床症状时进行。

要点

  • 8项研究523例患者,18F-FDG PET管理改变率范围28.6%-79.2%,合并61.4%。
  • 非小细胞肺癌亚组(常规影像异常、标志物升高或症状)合并管理改变率62.2%。
  • 作者建议对常规影像可疑或提示复发/转移、标志物升高或有症状者行18F-FDG PET。

核心结论

  • 18F-FDG PET对复发肺癌患者的管理有重大影响,管理改变合并率为61.4%(95%CI 49.5%-72.7%)。
  • 作者建议对肺癌患者进行18F-FDG PET,尤其是随访中常规影像可疑或提示复发/转移、肿瘤标志物升高或出现临床症状的病例。

研究设计与样本

  • 系统检索Medline和Embase数据库的英文文献,纳入关于PET检测复发/转移对肺癌患者管理影响的所有已发表研究。
  • 共纳入8项研究、523例患者,计算管理改变率(FDG PET后管理改变患者占接受FDG PET患者的百分比),使用MedCalc统计软件14.12.0版分析。

主要发现

  • 18F-FDG PET检测肺癌复发/转移的管理改变率范围为28.6%至79.2%,合并效应量为61.4%(95%CI 49.5%-72.7%;I²=85.7%)。
  • 亚组分析中,非小细胞肺癌患者(指征为常规影像异常发现、肿瘤标志物升高和临床症状)的合并管理改变率为62.2%(95%CI 44.2%-78.5%;I²=88.0%)。

关键数值与推荐

  • 管理改变率定义为FDG PET后管理改变患者数占接受FDG PET患者数的百分比。
  • 总体合并管理改变率为61.4%(95%CI 49.5%-72.7%;I²=85.7%)。
  • 非小细胞肺癌亚组合并管理改变率为62.2%(95%CI 44.2%-78.5%;I²=88.0%)。

临床怎么用

  • 作者建议对肺癌患者进行18F-FDG PET,尤其是随访中常规影像可疑或提示复发/转移、肿瘤标志物升高或出现临床症状的病例。

局限性

  • 异质性I²=85.7%。
  • 非小细胞肺癌亚组异质性I²=88.0%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The incidence of lung cancer has increased steadily. We meta-analyzed to assess the impact of 18F-FDG PET on the management of lung cancer to detect recurrence/metastasis. MATERIALS AND METHODS: We performed systematic searches of Medline and Embase databases for English-language publications. All published studies regarding the impact of PET on the management of patients with lung cancer in detection of recurrence/metastasis were searched. The proportion of management change (%) defined as the percentage of patients who changed management after FDG PET to patients who had FDG PET was calculated. The data from each study were analyzed using MedCalc Statistical Software version 14.12.0 (MedCalc Software, Ostend, Belgium). RESULTS: Eight studies including 523 patients were eligible for inclusion in the study. The impact of 18F-FDG PET for the purpose of detecting recurrence/metastasis in patients with lung cancer was evaluated using management change rates, which were ranged from 28.6% to 79.2% with a pooled effect of 61.4% (95% confidence interval, 49.5%-72.7%; I2 = 85.7%). In a subgroup analysis, impact of 18F-FDG PET was evaluated in studies of patients with non-small cell lung cancer with indication of abnormal findings of conventional imaging, elevated tumor markers, and clinical symptoms with the pooled rate of management change of 62.2% (95% confidence interval, 44.2%-78.5%; I2 = 88.0%). CONCLUSIONS: We have highlighted that 18F-FDG PET has a major impact on the management of patients with recurrent lung cancer. These findings suggest that 18F-FDG PET should be performed in patients with lung cancer, especially in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging, elevated tumor markers, or clinical symptoms during follow-up.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yoon HJ, Pak K. Impact of Follow-up 18F-FDG PET on the Management in Patients With Lung Cancer: A Meta-analysis. Clin Nucl Med. 2021. PMID: 34735409. doi:10.1097/RLU.0000000000003880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。